MEDICLIN AG

MED

Equity

ISIN DE0006595101 / Valor 1158721

Xetra (2024-11-21)

EUR 2.60%

MEDICLIN AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

MEDICLIN AG is a healthcare provider based in Germany, specializing in a comprehensive range of medical services. The company operates across the healthcare spectrum, focusing on acute care, rehabilitation (post-acute care), and inpatient nursing care services. With a network of facilities throughout Germany, MEDICLIN is positioned to offer a continuum of care to patients, encompassing immediate medical treatment, recovery, and long-term care. This integrated approach ensures that patients receive tailored healthcare services designed to meet their individual needs, from initial diagnosis through to rehabilitation and beyond. MEDICLIN's commitment to offering professional medical services is central to its operations, aiming to provide high-quality care across its various healthcare domains.

Summarized from source with an LLMView SourceSector: Healthcare

High Occupancy Rate

A rising occupancy rate with relation to medical, therapeutic, and nursing care services led to sales and earnings growth within the Group. In the first six months of 2024, the number of inpatients treated dropped slightly by 1.8% to 53,081 patients, while the occupancy rate rose by 1.6 percentage points to 85.2% compared to the prior-year period.

Sales and Operating Result

In the first six months of 2024, MEDICLIN AG's Group sales of EUR 368.0 million were up EUR 3.2 million or 0.9% on the first six months of 2023. Adjusted for benefits under the protective shield to manage the COVID-19 pandemic and divestments, Group sales rose by EUR 22.8 million or 6.8%. The Group generated a Group operating result of EUR 11.9 million in the first six months of 2024, which was EUR 0.6 million above the prior-year period.

Financial Position and Net Assets

A total (gross) sum of EUR 19.7 million was invested in the first six months of the 2024 financial year (6M 2023: EUR 16.7 million). Cash and cash equivalents as of 30 June 2024 amounted to EUR 113.5 million (31.12.2023: EUR 115.3 million). This item will presumably contain a total of about EUR 19.6 million in expected repayments to be made in the course of the year for benefits received under the protective shield to manage the COVID-19 pandemic.

Detailed Outlook for 2024

The Management Board issued more details concerning the forecasts for the 2024 financial year that had already been updated in the interim report for the first quarter. The annual forecast for sales and the Group operating result was last updated in May due to changes in the acute and post-acute segments. The Management Board continues to expect a sales decline of 0.0% to 2.0% in the current financial year. The Group operating result for the financial year is now expected to range between EUR 33.0 million and EUR 39.0 million.

Results of Operation

Group sales in the first six months of the 2024 financial year were up on the previous year’s value, increasing by EUR 3.2 million or 0.9%. The Group operating result improved by EUR 0.6 million to EUR 11.9 million. The financial result of EUR –10.7 million was EUR 0.4 million below the previous year’s level (6M 2023: EUR –10.3 million). The total consolidated result attributable to shareholders of MEDICLIN Aktiengesellschaft was EUR 0.6 million (6M 2023: EUR 4.8 million). Earnings per share came to EUR 0.01 (6M 2023: EUR 0.10).

Summarized from source with an LLMView Source

Key figures

-1.52%1Y

-35.3%3Y

-50.5%5Y

Performance

43.3%1Y

38.7%3Y

37.3%5Y

Volatility